Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5015202 | 0.99 | NPSR1 (0.67) | NPSR1ALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL27857138 | 0.88 | NPSR1 (0.72) | NPSR1ALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL5360911 | 0.86 | LMNA (0.59) | NPSR1ALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL4428781 | 0.85 | LMNA (0.58) | NPSR1ALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL27812799 | 0.85 | ALDH1A1 (0.55) | NPSR1ALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL28949192 | 0.84 | HPGD (0.68) | NPSR1ALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL16509336 | 0.84 | MAPT (0.58) | NPSR1ALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL14050551 | 0.82 | LMNA (0.55) | NPSR1ALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL7239112 | 0.81 | HPGD (0.65) | NPSR1ALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL4428794 | 0.80 | LMNA (0.53) | NPSR1ALDH1A1MAPTHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020119590-A1 | 3-CYANOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR, AND USES THEREOF. | 中国科学院上海药物研究所 | 2020-06-18 | — | — | WO | disclosed |
| EP-2044050-A1 | NEW PYRIDINE ANALOGUES | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009011627-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | WO | disclosed |
| US-20080312208-A1 | Pyridine Analogues | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| EP-1904474-A1 | NEW PYRIDINE ANALOGUES | AstraZeneca AB (SE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2008004946-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007008140-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312208-A1 | Pyridine Analogues | P2RY12, P2RY11, P2RY1 | NPSR1 1075/4885ALDH1A1 1274/4885MAPT 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.